JP2023531919A5 - - Google Patents

Info

Publication number
JP2023531919A5
JP2023531919A5 JP2022578616A JP2022578616A JP2023531919A5 JP 2023531919 A5 JP2023531919 A5 JP 2023531919A5 JP 2022578616 A JP2022578616 A JP 2022578616A JP 2022578616 A JP2022578616 A JP 2022578616A JP 2023531919 A5 JP2023531919 A5 JP 2023531919A5
Authority
JP
Japan
Prior art keywords
dosage form
weeks
patient
form according
administered daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022578616A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531919A (ja
JP7805969B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/038789 external-priority patent/WO2021262914A1/en
Publication of JP2023531919A publication Critical patent/JP2023531919A/ja
Publication of JP2023531919A5 publication Critical patent/JP2023531919A5/ja
Application granted granted Critical
Publication of JP7805969B2 publication Critical patent/JP7805969B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022578616A 2020-06-24 2021-06-24 強迫性障害を治療するための組成物及び方法 Active JP7805969B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043681P 2020-06-24 2020-06-24
US63/043,681 2020-06-24
PCT/US2021/038789 WO2021262914A1 (en) 2020-06-24 2021-06-24 Compositions and methods for treating obsessive-compulsive disorder

Publications (3)

Publication Number Publication Date
JP2023531919A JP2023531919A (ja) 2023-07-26
JP2023531919A5 true JP2023531919A5 (cg-RX-API-DMAC7.html) 2024-06-28
JP7805969B2 JP7805969B2 (ja) 2026-01-26

Family

ID=79281806

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022578616A Active JP7805969B2 (ja) 2020-06-24 2021-06-24 強迫性障害を治療するための組成物及び方法

Country Status (12)

Country Link
US (1) US20230181541A1 (cg-RX-API-DMAC7.html)
EP (1) EP4171554A4 (cg-RX-API-DMAC7.html)
JP (1) JP7805969B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230027189A (cg-RX-API-DMAC7.html)
CN (1) CN115968312A (cg-RX-API-DMAC7.html)
AU (1) AU2021297249A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025901A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187323A1 (cg-RX-API-DMAC7.html)
IL (1) IL299301A (cg-RX-API-DMAC7.html)
MX (1) MX2022016174A (cg-RX-API-DMAC7.html)
PH (1) PH12022553441A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021262914A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP2400349A1 (hu) * 2024-07-05 2026-01-28 Egis Gyógyszergyár Zrt. Troriluzole-hidroklorid-sók

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2819303T3 (es) 2005-04-05 2021-04-15 Univ Yale Agentes moduladores del glutamato en el tratamiento de trastornos mentales
DK3265448T3 (da) 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf
DK3297619T3 (da) 2015-05-22 2022-08-15 Vistagen Therapeutics Inc Terapeutiske anvendelser af L-4-chlorkynurenin
US10751345B2 (en) 2018-02-21 2020-08-25 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
CN112203692A (zh) 2018-05-27 2021-01-08 拜尔哈文制药股份有限公司 利鲁唑口腔崩解片用于治疗疾病的用途
JP2021530543A (ja) 2018-07-22 2021-11-11 バイオヘイブン・セラピューティクス・リミテッドBiohaven Therapeutics Ltd. アルツハイマー病を処置するためのリルゾールプロドラッグの使用
CN112584831A (zh) 2018-08-16 2021-03-30 拜奥海芬治疗学有限公司 利鲁唑口腔崩解片用于治疗疾病的用途

Similar Documents

Publication Publication Date Title
EP2435041B1 (en) Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
CA2529742A1 (en) Composition of a vegf antagonist and an anti-proliferative agent
JP2017529382A5 (cg-RX-API-DMAC7.html)
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
Younis et al. CGRP receptor antagonists (gepants)
JP2021530543A5 (cg-RX-API-DMAC7.html)
WO2009104149A1 (en) Combination comprising paclitaxel for treating ovarian cancer
KR20050085681A (ko) 프로테아제 억제제와 같은 사이토크롬 p450의 억제제와함께 비-뉴클레오시드 역전사효소 억제제(nnrti)를함유하는 배합물의 용도
JP2005525409A5 (cg-RX-API-DMAC7.html)
JP2025517509A5 (cg-RX-API-DMAC7.html)
KR20050075012A (ko) 항암제에 의해 유발된 말초신경증의 예방 및/또는 치료를위한 아세틸-l-카르니틴
WO2018132791A1 (en) Treatment of neurodegenerative conditions by disruption of rhes
US20240207199A1 (en) Fluorocarbon compositions and methods for enhancing immunotherapy
JP2024518426A5 (cg-RX-API-DMAC7.html)
US20210386736A1 (en) Combination therapy for treating cancer
HUP0202120A2 (hu) Daganatellenes kombináció
Sims-McCallum Triple antifungal therapy for the treatment of invasive aspergillosis in a neutropenic pediatric patient.
CN112533605A (zh) 用于治疗癌症的组合疗法
Kim et al. Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer
JP6243850B2 (ja) 抗がん剤による末梢神経障害の予防、治療、または軽減剤
HK40040830A (en) Combination therapy for treating cancer
Keady et al. Caspofungin in the treatment of invasive fungal infections
US20240122916A1 (en) Effect of YEL002 on Conditions and Diseases
HK40040825A (zh) 用於治疗癌症的组合疗法
EP4153180A1 (en) Combination therapy for treating cancer